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Background: The use of budesonide/formoterol in a single inhaler for both maintenance and reliever therapy is a
recommended option for treatment of persistent asthma not responding well to inhaled corticosteroid (ICS) alone.
Methods: This was a multi-centre open-label study on patients whose asthma condition remained inadequately
controlled by various asthma treatments other than budesonide/formoterol. After a 2-week run-in period, eligible
patients underwent a 12-week treatment period with budesonide/formoterol (Symbicort SMARTW, 160/4.5 μg) twice
daily plus as needed. Patient’s asthma control and quality of life were assessed using the 5-item Asthma Control
Questionnaire (ACQ-5) and the standardized Asthma Quality of Life Questionnaire (AQLQ-S), respectively.
Results: A total of 862 eligible asthma patients who have had asthma for a mean duration of 10.73 ± 12.03 years
entered a 12-week treatment with budesonide/formoterol maintenance and reliever therapy. During treatment, ACQ-5
score improved significantly by 0.58 ± 0.93 (95% CI, 0.51 to 0.64, P < 0.0001) from the baseline level of 1.62 ± 1.00. AQLQ
(S) score improved by 0.70 ± 0.89 (95% CI, 0.64 to 0.76, P < 0.0001) from baseline. Asthma symptom score was also
reduced significantly (P < 0.0001); between run-in and treatment periods, night- and day-time symptom scores were
reduced by 0.32 ± 0.54 (95% CI, 0.28 to 0.35) and 0.30 ± 0.52 (95% CI, 0.27 to 0.34), respectively. The percentage of
nights with awakenings due to asthma symptoms was reduced by 11.09 ± 26.13% (95% CI, 9.34 to 12.85%), while the
percentage of asthma-control and symptom-free days increased by 20.90 ± 34.40% (95% CI, 18.59 to 23.21%)
and 23.89 ± 34.62% (95% CI, 21.56 to 26.21%), respectively (P < 0.0001). Together with the improvement in
asthma control, the number of night- and day-time inhalations of as-needed reliever medication decreased by
0.30 ± 0.82 (95% CI, 0.24 to 0.35) inhalations and 0.30 ± 0.97 (95% CI, 0.23 to 0.36) inhalations, respectively (P < 0.0001).
No unexpected adverse events were reported.
Conclusion: During treatment of inadequately controlled asthmatic patients with budesonide/formoterol maintenance and
reliever therapy, significant improvement in patients’ asthma control and reductions in asthma symptoms and as-needed
medication use was observed. Patients’ quality of life was improved and the treatment was well tolerated.
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Inhaled corticosteroid (ICS) is the first-line treatment for
the management of asthma not controlled by on-demand
short-acting β2 agonists (SABA), and is the mainstay of
asthma therapies today [1,2]. A SABA is often prescribed
with ICS for relief of occasional breakthrough symptoms
during ICS treatment, but overuse of SABA for quick re-
lief of asthma symptoms has been associated with poor
asthma control [3]. Achieving and maintaining asthma
control with the minimal effective dose of medication(s)
used is the goal of all asthma therapies. But in reality, a
large proportion of patients undergoing various asthma
treatments considered conventional best practices fail to
achieve and/or maintain full asthma control [4,5]. Com-
plexity of treatment regimens, poor adherence and flawed
inhalation techniques are known factors contributing to
suboptimal asthma treatment outcomes. For adult pa-
tients whose asthma remains uncontrolled despite regular
inhalation of a low-to-medium dose of ICS, current clin-
ical practice guidelines recommend a step-wise approach
that is based on patient’s attainment of his/her asthma
control, which might include increasing the existing low-
dose ICS inhalation or adding on to low-dose inhaled ICS
therapy a long-acting β2 agonist (LABA) for control of
lung function and symptoms, and to reduce the risk of ex-
acerbations, and optionally, an additional SABA for as-
needed rapid relief of breakthrough symptoms in poorly
controlled cases [6,7]. If this approach fails to control the
asthma, a further stepwise addition of a leukotriene recep-
tor antagonist (LTRA) or theophylline could be consid-
ered. Clinical evidence suggests that the addition of a
LABA could provide better asthma control than the mere
upward titration of the patient’s ICS dose [8]. Budesonide/
formoterol in a single inhaler for both maintenance and
reliever therapy is now an established therapeutic option
for management of inadequately controlled asthma. This
single inhaler budesonide/formoterol maintenance and re-
liever therapeutic strategy is an approach recognised by
regulatory authorities in many countries and is now
recommended by the Global Initiative for Asthma (GINA)
for treatment of adult patients with uncontrolled asthma,
which GINA defines as having an exacerbation or at least
three of the following in a given week: daytime symptoms
>2 times/week, any limitation of activities, any nocturnal
symptoms/awakenings, need for reliever treatment >2
times/week or lung function <80% predicted normal [6].
In controlled clinical trials, the single inhaler budesonide/
formoterol maintenance and reliever therapeutic approach
has been shown to be more effective than conventional
best practices in achieving asthma control, with a safety
profile that is similar to treatment with ICS alone adminis-
tered at higher doses [9-14]. A recent post-hoc analysis of
five large clinical trials (>12000 patients) comparing
budesonide/formoterol single inhaler maintenance andreliever therapy with other treatments shows it as a highly
effective option for patients requiring treatment adjust-
ments across Steps 2 to 4 in the GINA treatment guide-
lines [15]. However, other than the evidence obtained
from clinical trials, there is a paucity of information on
the effectiveness of budesonide/formoterol maintenance
and reliever therapy in real-life clinical practice. This study
was designed to assess in a real-life setting the effective-
ness of the single inhaler budesonide/formoterol mainten-
ance and reliever therapy (Symbicort SMARTW) in the
management of asthma inadequately controlled by pa-
tients’ prior other asthma medications.
Methods
Study design
This was a 12-week multi-centre open-label therapeutic
Phase IV study designed to evaluate the effects of a
single inhaler budesonide/formoterol maintenance and
reliever therapy on asthma patients in 5 countries/
areas across Asia whose asthma condition remained
inadequately controlled despite having been on con-
tinuous treatment with various asthma therapies, except
budesonide/formoterol, for at least 4 weeks. The study
was designed to mimic as much as possible routine clin-
ical practice to minimise interference with physicians’ and
patients’ behaviours that might influence outcomes.
Study population and sample size
The target population were patients aged 18 years and
above with confirmed diagnosis of asthma as defined by
GINA 2007 guidelines [16], who have had asthma for at
least 6 months, were on continuous asthma treatment
within the 4 weeks preceding screening and whose
asthma condition was partly controlled or uncontrolled.
The eligible patient must have demonstrated reversible
airway obstruction, defined as an increase in FEV1 ≥12%
and 200 ml from pre-bronchodilator value. Patients were
excluded if they were found to have any of the following:
chronic obstructive pulmonary disease; previous treat-
ment with budesonide/formoterol; current use of any
β–blocker therapy; use of ICS within the 30 days pre-
ceding this study enrolment; or a smoking history of ≥10
pack-years. Additionally, to enter the study treatment
period, patient must have experienced no asthma exacer-
bation during the run-in to treatment.
Study objectives
The primary objective of the study was to compare, at a re-
gional level, the effects of inhaled budesonide/formoterol
maintenance and reliever therapy on partially controlled or
uncontrolled asthma patient with the patient’s previous
therapy by assessing the changes in the Asthma Control
Questionnaire (ACQ-5) score. The secondary objectives of
the study were: (i) to document the well-being of patients
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therapy in different countries/areas within the general
practice setting, by assessing the change in ACQ-5 score
from baseline at country/area level; (ii) to assess the clinical
effectiveness of budesonide/formoterol maintenance
and reliever therapy on patients’ quality of life, by
change in standardized Asthma Quality of Life Ques-
tionnaire (AQLQ-S) and overall scores from baseline
at regional level; and (iii) to document the usage and com-
pliance, and also patient’s perception of budesonide/
formoterol maintenance and reliever therapy within gen-
eral practice setting. Study medication use including mean
number of total and as-needed inhalations per day, num-
ber (%) of patients taking more than a total of 12 inhala-
tions on at least 1 day and number (%) of patients taking
at least 9 inhalations in total every day for more than
2 weeks were documented.
Study interventions, procedures and outcome measures
The study flow is depicted in Figure 1. Eligible patients
went through a 2-week run-in period during which time
they were kept on their existing asthma medications,
followed by a switch to a 12-week treatment with a sin-
gle inhaler therapy containing budesonide (160 mg) and
formoterol (4.5 mg) (budesonide/formoterol; Symbicort
SMARTW, 160/4.5; AstraZeneca, Lund, Sweden), during
which time, patients self-administered a one inhalation,
twice daily regimen of the budesonide/formoterol, with
one inhalation in the morning and one inhalation in the
evening, plus as-needed additional inhalations in response
to symptoms. Patients’ asthma control and quality of life
were assessed using the validated 5-item ACQ-5 and the
standardized AQLQ-S, respectively [17-19]. These assess-
ments were made at baseline (Visit 2) and then at Visit 3,
four weeks into the treatment, Visit 4, eight weeks into
the treatment, and again at Visit 5, twelve weeks into theFigure 1 Study flow chart.treatment. For both the ACQ-5 and AQLQ-S, a minimal
important difference (MID) for clinical significance was
set at 0.5 unit change in score from baseline level [20]. To
assess lung function, patient’s forced expiratory volume in
one second (FEV1) was measured at baseline (Visit 2), just
before the initiation of treatment with Symbicort mainten-
ance and reliever therapy, and at Visit 3, four weeks into
the treatment, and again at Visit 5, twelve weeks into the
treatment. FEV1 was measured using a standard spirom-
etry method [21]. Throughout the study duration, the pa-
tient recorded on a diary card the following outcome
measures: (i) asthma symptom score, day and night; (ii)
nights with awakening(s) due to asthma symptoms; and
(iii) number of inhalations of budesonide/formoterol.
Post-treatment changes in these parameters were then
evaluated with reference to the pre-treatment (baseline)
levels.
Prior to commencement of this study, approvals to
conduct the study were obtained from the appropriate
independent ethics committee and/or institutional re-
view boards governing the respective participating cen-
tres in each country/area (refer to full list under
Appendix I). The study was performed in accordance
with the principles of the International Conference on
Harmonisation (ICH) Harmonised Tripartite Guideline
for Good Clinical Practice (GCP). Written informed
consent was obtained from each participating patient be-
fore he/she proceeded to participate in the study.
Evaluation of safety
Safety data were collected throughout the study duration.
Adverse events, serious adverse events and discontinuations
due to adverse events were recorded as when reported by
study investigators and coded according to MedDRA (Ver-
sion 12.0). Safety evaluation included the data collected from
all patients who took at least one dose of the investigational
Table 1 Study population (Full analysis set)
China India Indonesia Taiwan Thailand All
Patients in full
analysis set
407 162 61 103 129 862
Patients in safety
analysis set
407 162 61 103 129 862
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have been collected post-initiation of the study treatment.
Statistical methods
The study population size was estimated according to
the precision with which the effect size is set to be
reported. Based on the primary variable of this study,
which is the mean change in ACQ-5 score from baseline
level, we determined a sample size of about 1000 pa-
tients in the entire Asian region to give us a 95% confi-
dence interval (CI) with an approximate width of 0.12
units when standard deviation (SD) is 1.0 unit. All statis-
tical analyses were performed on an intention-to-treat
basis, using data from all participating patients who had
taken at least one dose of the investigational drug and
had data collected after initiation of the drug treatment.
The primary outcome variable, change in ACQ-5 score
from baseline to treatment period, was analysed using
paired t-test, with significance set at the 5% level. A
change of ≥0.5 in the score was deemed clinically im-
portant. The changes in AQLQ-S overall and domain
scores were analysed in a similar way. G-mean FEV1 was
derived via a multiplicative analysis of variance with pa-
tient, period and treatment set as fixed factors. FEV1 and
all other secondary patient-reported outcomes were
analysed as change from baseline level using paired
t-test, at the 2-sided 5% level of significance. Safety data
were analysed using descriptive statistical methods.
Results
Patients’ demographics and baseline characteristics
Between July 2009 and August 2010, a total of 1022 eli-
gible asthma patients were enrolled from 51 study centres
across China, India, Indonesia, Thailand and Taiwan.
Amongst them, 862 (84.3%) patients entered into the
study treatment period. There were 407 males and 455 fe-
males with mean age (± SD) of 44.7 ± 13.7 years. Together,
they have had asthma for a mean duration of 10.73 ±
12.03 years, and the majority of these patients (69%) were
being treated with Salbutamol (393 patients; 45.6%) or
combination of Fluticason and Salmeterol (202 patients;
23.4%), while the rest were treated with various other
asthma medications. Most patients were also on concomi-
tant ICS. At entry to this study, 719 patients (83.4%) were
on ICS, with 525 patients (60.9%) on LABA plus ICS, and
135 patients (15.7%) on SABA plus ICS.
Of the patients who entered into the study treatment
period, 66 (7.7%) of them discontinued from the study
for various reasons, which include adverse events (15 pa-
tients), pregnancy (1 patient), self-withdrawal (13 patients),
deviations from study protocol (6 patients), incorrect en-
rolment (8 patients) and lost to follow-up (23 patients).
The 862 patients who took at least one dose of the investi-
gational drug, budesonide/formoterol, formed the set ofsubjects for analysis of both the efficacy and safety out-
comes of this study (Table 1). The demographic and base-
line characteristics of the subjects in the full analysis set
are summarised in Table 2.Assessments of impact on patients’ asthma control
Change in ACQ-5 score from baseline at regional level
At the regional level, patients’ asthma control signifi-
cantly improved during treatment with budesonide/
formoterol maintenance and reliever therapy. This is
reflected by the consistent reduction in mean overall
ACQ-5 score from baseline to 4, 8, and 12 weeks of the
therapy (Figure 2 and Table 3). A significant decrease in
ACQ-5 score was evident from 4 weeks post-initiation
of treatment with budesonide/formoterol maintenance
and reliever therapy, indicating early onset of improve-
ment in asthma control. During the treatment period,
overall mean ACQ-5 score improved significantly by
0.58 ± 0.93 (95% CI, 0.51 to 0.64; P < 0.0001). Clinically
important improvement in ACQ-5 score (change ≥MID
of 0.5) was observed by 8 weeks of treatment. During
treatment, 48.2% of the patients experienced improve-
ment in symptoms, while only 8.8% experienced worsen-
ing of symptoms.Change in ACQ-5 score from baseline at country/area level
Significant reduction in mean ACQ-5 score of patients was
observed in all 5 participating countries during the period
they were treated with budesonide/formoterol mainten-
ance and reliever therapy (P < 0.0001 to P = 0.0089), indi-
cating significant improvements in asthma control across
the region during the treatment (Figure 3 and Table 4). Sta-
tistically significant changes were observed from as early as
4 weeks after initiation of the treatment. However, the
quantum of change in ACQ-5 scores differed significantly
between study populations in the various countries/areas
(P < 0.0001); the change was highest amongst the study
population in Indonesia, followed by that of those in India,
China, Thailand and Taiwan. Improvement in asthma con-
trol reached clinical importance (change in ACQ-5 score ≥
MID of 0.5) only in the study populations in China, India
and Indonesia; in China and Indonesia, clinically important
improvement in ACQ-5 score was achieved by 4 weeks
post-initiation of treatment with budesonide/formoterol
maintenance and reliever therapy.





patients N = 862
Sex Male 407 (47.2)
Female 455 (52.8)
Age (years) n 862
Mean (SD) 44.7 (13.7)
Range 18 - 81
Race Asian 862 (100.0)
BMI (kg/m**2) n 862
Mean (SD) 24.36 (4.10)
Range 14.2 - 47.5
Time since diagnosis (years) n 862
Mean (SD) 10.73 (12.03)
Range 0.1 - 60.0
Smoking Non smoker 744 (86.3)
Ex-smoker 84 (9.7)
Occasional smoker 18 (2.1)
Habitual smoker 16 (1.9)
Pack-years n 116
Mean (SD) 4.8 (2.9)
Range 0 - 15
Inhaled GCS at entry No 143 (16.6)
Yes 719 (83.4)
Inhaled GCS at entry:
dose (ug/day)
n 317
Mean (SD) 557.8 (321.5)
Range 50 - 1600
FEV1 (L) n 862
Mean (SD) 2.063 (0.709)
Range 0.69 - 4.63
FEV1% of predicted normal * n 862
Mean (SD) 70.38 (17.37)
Range 22.4 - 124.3
FEV1% Reversibility n 862
Mean (SD) 26.50 (15.15)
Range 9.8 - 139.5
a FAS: All enrolled subjects except for screening failure.
* Predicted normal FEV1 value (post-bronchodilator) was calculated according
to ERS [22].
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night, inhalations of medications, asthma-control and
asthma symptom-free days
Patients’ mean asthma symptom score was significantly
reduced (P < 0.0001) while they were on treatment with
budesonide/formoterol maintenance and reliever ther-
apy. From run-in to treatment period, night- and day-
time symptom score improved by 0.32 ± 0.54 (95% CI,0.28 to 0.35) and 0.30 ± 0.52 (95% CI, 0.27 to 0.34),
respectively. The percentage of days with awakening(s)
due to asthma symptoms during the night was reduced
by 11.09 ± 26.13% (95% CI, 9.34 to 12.85%; P < 0.0001),
while the percentage of asthma-control and symptom-
free days increased by 20.90 ± 34.40% (95% CI, 18.59 to
23.21%) and 23.89 ± 34.62% (95% CI, 21.56 to 26.21%),
respectively (P < 0.0001).
During the run-in period, the number of inhalations
(mean ± SD) of as-needed medications was 0.57 ± 0.88
inhalations during night-time and 0.65 ± 1.04 inhalations
during day-time. The corresponding numbers of night-
time and day-time inhalations during treatment period
was 0.27 ±0.44 and 0.36 ± 0.56 inhalations, respectively.
Along with that, the number of inhalations of as-needed
reliever medications for night- and day-time was signifi-
cantly reduced by 0.30 ± 0.82 (95% CI, 0.24 to 0.35) inha-
lations and 0.30 ± 0.97 (95% CI, 0.23 to 0.36) inhalations,
respectively (P < 0.0001). Concurrently, the percentage of
as-needed medication free days increased by 11.90 ±
44.65% (95% CI, 8.90 to 14.89%; P < 0.0001). During the
period patients were on budesonide/formoterol mainten-
ance and reliever therapy, only 1 patient (0.1%) had used
SABA concomitantly for relief of symptoms.
Change in forced expiratory volume in one second (FEV1)
from baseline level
Patients’ lung function improved during treatment with
budesonide/formoterol maintenance and reliever ther-
apy. This was reflected by a significant increase in FEV1
G-mean value from baseline level as early as 4 weeks
post-initiation of treatment (P < 0.0001), indicating an
early onset in recovery of impaired lung function
(Figure 4 and Table 5). At baseline, mean FEV1 (mean ±
SD) was 1.96 ± 0.76 L and G-mean FEV1 (G-mean ±
CV%) was 1.82 ± 40.78 L. During the 12 weeks of treat-
ment, the overall increase in mean FEV1 from baseline
was 0.17 ± 0.35 (95% CI, 0.15 - 0.20) L; the correspond-
ing increase in G-mean FEV1 was 1.10 ± 19.33 (95% CI,
1.08 - 1.11) L (P < 0.0001).
Assessment of impact on patients’ Quality of life
Change in AQLQ-S domains and overall scores from
baseline (regional level)
During treatment with budesonide/formoterol mainten-
ance and reliever therapy, patients’ overall AQLQ-S
score improved by 0.70 ± 0.89 (95% CI, 0.64 to 0.76)
from baseline level (P < 0.0001), demonstrating a signifi-
cant overall improvement in patients’ quality of life
across the region. Significant improvement was evident
from as early as 4 weeks into the therapy, and the im-
provement continued throughout the treatment period
(Table 6). Clinically important change (difference ≥MID
of 0.5) was evident from 8 weeks post-initiation of
Figure 2 Mean ACQ-5 scores following initiation of treatment
with budesonide/formoterol maintenance and reliever therapy
(regional level). * denotes significant difference from baseline level.
Visit 2 = baseline.
Zhong et al. BMC Pulmonary Medicine 2013, 13:22 Page 6 of 12
http://www.biomedcentral.com/1471-2466/13/22budesonide/formoterol maintenance and reliever therapy.
While 52.9% of the patients experienced improvement in
everyday functioning and well-being, only 5.1% of them
experienced worsened conditions. Overall scores for
symptoms, activity limitations, emotion function and re-
sponse to environmental stimuli were likewise signifi-
cantly increased during the treatment period (P < 0.0001),
with significant improvement seen from as early as 4 weeks
after initiation of treatment with budesonide/formoterol
maintenance and reliever therapy.
Change in AQLQ-S domains and overall scores from
baseline (country/area level)
Statistically significant improvement in overall AQLQ-S
score was observed in all 5 participating countries/areas
during treatment with budesonide/formoterol mainten-
ance and reliever therapy (P < 0.0001 to P = 0.0002). Sig-
nificant improvements from baseline levels were observed
by 4 weeks of treatment (P < 0.0001 to P = 0.0252). The
quantum of change however differed significantly be-
tween the populations studied in the various countries/
areas (P < 0.0001); the change from baseline level was
greatest in the study population in Indonesia, followed
by that of those in India, China, Thailand and Taiwan.
Clinically important change (difference ≥MID of 0.5)Table 3 Summary of mean values of overall ACQ-5 score at a
Variable Visit Observed value Chang
N Mean SD N
Overall score 2 854 1.62 1.00 -
3 833 1.16 0.88 826
4 803 1.01 0.85 796
5 794 0.92 0.85 787
Mean of 3-5 841 1.04 0.75 834in AQLQ-S score was observed only in Indonesia,
Thailand, China and India. Significant improvements
in individual domains (symptoms, activity limitations,
emotional function and response to environmental
stimuli) measured during treatment were also observed
in all the study populations in the 5 countries/area.
Safety
Amongst the 862 patients included in the safety analysis,
171 patients (19.8%) reported adverse events, and 12 pa-
tients (1.4%) reported serious adverse events. The most
frequently reported adverse events were nasopharyngitis
(3.4%), followed by upper respiratory tract infection
(3.2%), and asthma exacerbation (1.4%). The majority
(130 of 171) of the adverse events were of mild intensity.
Thirteen patients (1.5%) had their study medication
discontinued because of adverse events. Serious adverse
events were uncommon, with only 15 events reported in
12 patients, 8 of which were considered severe in inten-
sity, and one of them was life threatening. There were 3
cases of palpitations, the causality of which were judged
by the investigator as possibly related to budesonide/
formoterol maintenance and reliever therapy. Two of
the serious adverse events, an asthma exacerbation and
a myocardial infarction, resulted in death. Both deaths were
however considered unrelated to budesonide/formoterol
maintenance and reliever therapy.
Discussion
This study documents the baseline and treatment out-
come data collected during a 12-week budesonide/
formoterol maintenance and reliever therapy in 862
Asian patients with partially controlled or uncontrolled
asthma, treated in a real-life clinical practice setting.
During treatment with budesonide ⁄ formoterol mainten-
ance and reliever therapy, administered one inhalation,
twice daily for maintenance therapy, plus as-needed for re-
liever medication, patients whose asthma conditions were
not adequately controlled while on their previous medica-
tions had their asthma conditions significantly improved.
At baseline, the overall ACQ-5 of patients assessed in
the region was 1.62 ± 1.00, indicating generally poorly
controlled asthma in the study population. Following
the 12-week budesonide/formoterol maintenance andregional level
e from visit 2 (baseline) 95% CI Paired t-test
Mean SD Lower Upper p-value
- - - - -
−0.46 0.96 −0.52 −0.39 <.0001
−0.60 1.01 −0.67 −0.53 <.0001
−0.69 1.09 −0.77 −0.62 <.0001
−0.58 0.93 −0.64 −0.51 <.0001
Figure 3 Mean Change in ACQ-5 scores from baseline to
treatment period (by country/area). * denotes significant
difference from baseline level.
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nificantly to 0.92 ± 0.85 (P < 0.0001). Significant relief
of asthma symptoms was observed as early as 4 weeks
into budesonide⁄formoterol maintenance and reliever
therapy, while clinically important improvement was
observed by 8 weeks of treatment, indicating early im-
provement in asthma control after initiation of the ther-
apy. The improvement in asthma control was sustained
throughout the 12-week treatment period.
Along with improvements in asthma control, as-needed
use of reliever medication was significantly reduced;
patients experienced more reliever medication-free days
during budesonide/formoterol maintenance and reliever
therapy than during the run-in period (P < 0.0001). Pa-
tients’ diary records showed asthma symptoms and
night awakenings due to the symptoms were both signifi-
cantly reduced during the treatment period (P < 0.0001).
The percentage of both the asthma control days and
symptom-free days were significantly increased during
budesonide/formoterol maintenance and reliever therapy
(P < 0.0001). In addition, FEV1 levels measured before and
after budesonide/formoterol maintenance and reliever
therapy indicated a significant improvement in lung
function from the baseline level during the therapy
(P < 0.0001). As with the patient-reported outcomes
described above, improvement in lung function, asTable 4 Summary of period means of overall ACQ-5 score for
Overall score N Visit 2 (baseline) Mean of vis
Mean Range Mean Ra
Country or Area China 386 1.72 0.0 - 5.0 1.14 0.0
India 159 1.87 0.0 - 5.4 1.12 0.0
Indonesia 61 1.78 0.0 - 3.8 0.61 0.0
Taiwan 100 1.11 0.0 - 4.8 0.89 0.0
Thailand 128 1.31 0.0 - 3.6 0.95 0.0measured by FEV1, were apparent from as early as 4 weeks
after initiation of budesonide/formoterol maintenance and
reliever therapy and was sustained throughout the 12-
week treatment period.
Together with better asthma control, patients’ quality of
life, as assessed by the AQLQ-S overall and domain scores,
improved significantly during budesonide/formoterol main-
tenance and reliever therapy. At the regional level, the over-
all changes in AQLQ-S scores from baseline to treatment
period were both statistically significant and clinically im-
portant, with about half of the patients treated showing im-
provements in asthma control, as well as in their everyday
functioning and well-being.
At the country/area level, although the improvements
in asthma control and quality of life, as indicated by the
change in ACQ-5 and AQLQ-S scores from baseline to
treatment period, were statistically significant in all 5
participating countries/areas, clinically important change
in the ACQ-5 score was observed in China, India and
Indonesia, but not in Thailand and Taiwan. Similarly,
clinically important change in AQLQ-S score was evi-
dent in Indonesia, Thailand, China and India, but not in
Taiwan. Although, by 4 weeks of budesonide/formoterol
maintenance and reliever therapy, the changes in both
ACQ-5 and AQLQ-S scores already reached statistical
significance in all countries, clinically important differ-
ence in ACQ-5 score from baseline was only achieved in
China and Indonesia, while that of AQLQ-S score was
only achieved in China, India and Indonesia.
The reason behind the significant inter-country/area
difference in the treatment outcomes and the time lag in
achieving clinically important improvements in certain
countries is not clear. Although the wide difference in
sample size between the countries might have skewed
the statistics, the impact of sample size is probably min-
imal, judging from the fact that Indonesia, which has the
smallest sample size, had results that showed a most
pronounced improvement in asthma control in its study
population. It is possible that inter-country difference in
clinical management of asthma, which might also result in
differences in patients’ baseline variables, might have af-
fected the quantum of change observable post-treatment.
Moreover, outcome data could, at least in part, be affected
by the variation in disease epidemiology in the differentmean of visit 3–5 at country/area level
it 3-5 Mean change 95% confidence interval Paired t-test
nge Lower Upper p-value
- 4.4 −0.58 −0.67 −0.49 <.0001
- 3.3 −0.74 −0.92 −0.57 <.0001
- 2.9 −1.18 −1.40 −0.95 <.0001
- 2.9 −0.22 −0.38 −0.06 0.0089
- 2.9 −0.36 −0.48 −0.23 <.0001
Figure 4 G-mean FEV1 change from Visit 2 (baseline) and 95%
CI.
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are perceived across geographical and cultural barriers. In
a real-life study setting such as this one, few, if any, poten-
tial confounders could be controlled.
While the design of the study does not allow for any
conclusions regarding the effect of budesonide/formoterol
maintenance and reliever therapy, it being a within-group
comparison, the results are in line with what has been pre-
viously seen [23-26]. Owing to the study design, the
beneficial effect may be considered as a result of sim-
ply step-up therapy. However, patients in majority
(60.9%) were already on ICS plus LABA before entry.
Further improvement of symptoms and lung function
may be attributed to the SMART regimen. In addition,
the improvements in symptom control, lung function, and
reduction in as-needed reliever medications were compar-
able to those previously reported in earlier studies [24,27].
In terms of safety, budesonide/formoterol adminis-
tered one inhalation, twice daily as maintenance therapy,
plus as-needed as symptom reliever, was well tolerated
by patients during the 12-week treatment period. Only
19.8% of the treated patients reported adverse events,
and 1.4% of patients reported serious adverse events
during the study. The majority of the reported adverse
events were of mild intensity. Only 1.5% of the patients
presenting with adverse events had their study medication
discontinued because of the adverse events. There were 3
cases of palpitations possibly related to budesonide/Table 5 Mean values of FEV1 at a regional level
Variable Visit Observed value
N Mean SD Min Median Max N
FEV1 (L) 2 862 1.964 0.759 0.40 1.830 5.06 -
3 836 2.110 0.779 0.55 1.985 4.91 8
5 805 2.160 0.767 0.52 2.060 5.15 8
Mean of 3 and 5 840 2.131 0.761 0.54 2.028 4.66 8formoterol maintenance and reliever therapy. Two ad-
verse events (0.2%) resulted in deaths, but both were
considered unrelated to budesonide/formoterol main-
tenance and reliever therapy. There was no evidence of
overuse of budesonide/formoterol as a reliever medication.
Observations concerning safety of the treatment was in
line with the results of other studies on budesonide/
formoterol maintenance and reliever therapy [28,29], and
we did not identify any new safety-related issue with the
budesonide/formoterol maintenance and reliever therapy
during the 12-week treatment period.
In summary, the results are in line with previous find-
ings that a single inhaler therapy for asthma with com-
bined budesonide and formoterol as both maintenance
therapy and reliever provided better control of asthma
than conventional combination inhalers. Budesonide/
formoterol, administered one inhalation twice a day as
maintenance therapy and as-needed, was well tolerated.
Conclusions
During treatment of inadequately controlled asthmatic
patients with budesonide/formoterol maintenance and
reliever therapy, significant improvement in patients’
asthma control and reductions in asthma symptoms and
as-needed medication use was observed. Patients’ qual-
ity of life was improved and the treatment was well
tolerated.
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3 838 5.31 1.00 1.8 5.41 7.0 837 0.51 0.89 −3.8 0.39 4.5 0.45 0.57 <.0001 <.0001
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